Navigation Links
Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Date:11/10/2012

tment option for people living with advanced hepatitis C if proven in advanced trials."

Simeprevir, an investigational NS3/4A protease inhibitor jointly developed by Janssen and Medivir, is currently in Phase 3 studies as a once-daily treatment taken in combination with pegylated interferon and ribavirin for the treatment of genotypes 1 and 4 chronic hepatitis C. It is also being studied in separate Phase 2 trials with other direct-acting antiviral agents as part of interferon-free regimens, with and without ribavirin. This includes a recently initiated Phase 2a trial of an interferon-free regimen with simeprevir and TMC647055, Janssen's non-nucleoside polymerase inhibitor (NNI) currently in development for hepatitis C.

"We are encouraged by these data, which show sustained viral response and tolerability in both treatment-naive and more challenging-to-cure patients," said Maria Beumont, M.D., Medical Leader for simeprevir, Janssen Research & Development. "We look forward to further evaluating the utility of simeprevir in combination with other agents for the treatment of hepatitis C."

About the PILLAR & ASPIRE Trials  
In the two international, Phase 2b, randomized, double-blind, placebo-controlled studies, patients were either treatment naive (PILLAR) or treatment experienced (ASPIRE), and received pegylated interferon and ribavirin alone or in combination with once-daily simeprevir. In PILLAR, 309 treatment-naive hepatitis C patients received either 75 or 150 mg of once-daily simeprevir for 12 or 24 weeks plus pegylated interferon and ribavirin for 24 or 48 weeks depending on their response to treatment. In ASPIRE, 396 treatment-experienced patients received either 100 or 150 mg of once-daily simeprevir for 12, 24 or 48 weeks plus pegylated interferon and ribavirin for 48 weeks.

The post hoc analyses of PILLAR and ASPIRE presented at AASLD (abstracts 83 and 769) evaluated only patients receiving 150 m
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
2. Optimization of Comparative Efficacy Trials
3. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
4. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
5. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
6. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
7. FDAnews announces Fifth Annual Risk Management & Drug Safety Summit
8. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
9. Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
10. Compounding Pharmacy Safety: Dr. Paul Savage Published in IMJC Post #Meningitis Outbreak
11. Kansas Car Umbrella Encouraged By New Safety Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... S.C. , April 23, 2015 Once ... and strengthening our commitment to patient safety. ... the fight against infectious disease. The next ... Medical gas sensors are now mounted in the ... the need to open ceiling tiles potentially releasing dust ...
(Date:4/23/2015)... -- Research Solutions, Inc. (OTCQB: RSSS), a pioneer in providing on-demand ... life science companies, academic institutions, and other research intensive ... th Annual B. Riley & Co. Investor Conference ... Loews Hollywood Hotel in Los Angeles ... scheduled to present on Tuesday, May 12 th ...
(Date:4/23/2015)... AUGUSTA, Ga. , April 23, 2015 /PRNewswire/ ... of medical holography, has made its Voxgram hologram ... just-launched Kickstarter campaign: https://www.kickstarter.com/projects/629071847/holographic-optical-technologies?ref=nav_search ... first consumer product through the campaign, the eight-inch ... a reward, along with its more established, medical-grade ...
Breaking Medicine Technology:BeaconMedaes launches new Zone Valve Box Assembly 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 3Holographic Optical Technologies Launches Kickstarter, Offering True 3D Holograms 2
... Nov. 12 Zimmer Holdings, Inc. (NYSE: ZMH ; ... $1.0 billion of its senior unsecured notes in an underwritten ... 2019 and $500.0 million of 5.75% notes due 2039. The ... their Treasury benchmark, and the 30-year notes were priced at ...
... new treatment for autism appears to normalize brain function, ... BCIA-EEG. , In addition to high serotonin ... pattern reflecting impaired brain function, particularly in areas of ... bonding. , However, Quantitative EEG,s conducted ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3
(Date:4/24/2015)... Eastern Star Masonic Home is hosting an Open House to ... from 1:30-3:00 pm. , Residents from Boone and the surrounding ... opening of the new community room. Light refreshments will be ... to anyone who wishes to visit the rest of the ... be available for use by residents of the facility as ...
(Date:4/24/2015)... Buffalo, New York (PRWEB) April 24, 2015 ... has partnered with Allergy and Asthma Network (The Network), ... PURE Solutions will provide news, tips and information ... on The Network’s newly redesigned website. , The goal ... raising awareness about the travel needs of people with ...
(Date:4/24/2015)... 2015 E-Factor Diet claims to be a ... stress and allows people to enjoy food as rapid weight ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... blueprint that Jared used to lose weight, and all the ... included inside. This is a diet for people who are ...
(Date:4/24/2015)... Del Mar, CA (PRWEB) April 24, 2015 ... newest addition to the staff, Jamie Johansen. She will ... practice, including human resources, patient relations, and reporting. Jamie ... spa and cosmetic surgery sector as the new Practice ... Operations at LaserAway and Practice Manager at American Laser ...
(Date:4/23/2015)... 23, 2015 Fitnet , the only ... now, an accurate calorie counter during video exercise, is featured ... Health and Fitness categories in the Apple Watch App Store ... of the Digital age," now allows clients to use it ... only third party app providing accurate calorie burn counter, cardio ...
Breaking Medicine News(10 mins):Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:E-Factor Diet: Review Examining John Rowley’s Brand New Weight Loss Program Released 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 3
... discovered a protein signaling pathway that becomes hyperactivated in human ... be effective in the treatment of human sarcomas. The ... Cancer Cell . A team of researchers led ... and Chairman of the Department of Oncological Sciences at Mount ...
... St. Louis, MO 23 May, 2011 ... and medical information products and services, announced today ... (METI), a leading manufacturer of medical simulation and ... to release a turn-key health care education product ...
... researchers, including a number from the University of North Carolina ... the genome that contribute to the debilitating lung disease that ... provide insight into the causes of the wide variation in ... the way to new diagnostic markers and therapeutic approaches for ...
... the name of an infection that causes a series of reactions ... The problem for both patients and doctors is that the early ... a severe flu or winter vomiting disease. A researcher at Lund ... which shows both whether a patient has sepsis and how serious ...
... SUNDAY, May 22 (HealthDay News) -- New Swedish research ... major cardiovascular complications among patients who have a ... builds on earlier work that was published by the ... That study suggested that Inspra (eplerenone), an aldosterone antagonist, ...
... the Florida campus of The Scripps Research Institute have for ... natural product isolated from the bark of a plant widely ... foundation to develop an effective alternative to commonly prescribed narcotic ... in an advanced online edition of the journal Nature ...
Cached Medicine News:Health News:Mount Sinai researchers discover possible new target for sarcoma treatment and prevention 2Health News:Elsevier and METI collaborate to offer simulation technology for health science curriculums 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Quicker detection and treatment of severe sepsis 2Health News:Blood Pressure Drug Helps Those With Mild Heart Failure 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 3
... a foldable silicone IOL. It features a ... designed to be inserted with The UNFOLDER® ... is the first and only FDA-approved multifocal ... a full range of functional visionnear, intermediate, ...
... with optimum molecular weight and viscosity, so ... coats and protects the delicate structures of ... balance of cohesion, adhesion, and pseudoplasticity to ... phaco surgeon expects from an ophthalmic viscoelastic ...
... Healon GV is a sterile, non-pyrogenic, ... purified, noninflammatory, high molecular weight (average ... sodium hyaluronate. Healon GV contains 14 ... in a physiological sodium chloride-phosphate buffer ...
... PROVISC ophthalmic viscosurgical device is ... characterized by high molecular weight, ... tension. It provides excellent space ... is easily removed. It is ...
Medicine Products: